{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
dimethyl fumarate
to a specific field?
Status:
Investigational
Source:
NCT03860480: Not Applicable Interventional Completed Thoracic Surgery, Video-Assisted
(2018)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
Clin Nephrol. Feb 1986;25(2):70-4.: Not Applicable Human clinical trial Completed Hyperlipidemias/complications
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Pantetheine is the mercaptoethyl conjugated amide analog of pantothenic acid (Vitamin B5), an intermediate in the production of coenzyme A by the body. Pantetheine is part of two larger compounds (coenzyme A and acyl-carrier protein) that promote a large number of metabolic reactions essential for the growth and well-being of animals. Pantetheine has been found to ameliorate symptoms in various disease models but specifically in Pantothenate Kinase-Associated Neurodegeneration (PKAN). Pantetheine is usually administered in its disulfide form (i.e. pantethine) since pantethine is commercially available and is reduced to pantetheine in biological systems and pantethine was hydrolyzed to pantetheine and pantothenic acid prior to absorption. The applicability and efficacy of pantethine (therefore also pantetheine) as a clinical therapeutic however is hampered since both forms can be degraded by pantetheine present in the body.
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT02091362: Phase 2 Interventional Completed Type 2 Diabetes Mellitus
(2014)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Adomeglivant, also known as LY2409021, is a potent and selective glucagon receptor antagonist. Adomeglivant lowers blood glucose in healthy people and in those with type 2 diabetes. Blockade of glucagon signalling in patients with type 2 diabetes is well tolerated and results in substantial reduction of fasting and postprandial glucose with minimal hypoglycaemia, but with reversible increases in aminotransferases. Adomeglivant had been in phase II clinical trials by Eli Lilly for the treatment of type 2 diabetes mellitus. However, this research has been discontinued.
Status:
Class (Stereo):
CHEMICAL (RACEMIC)
Sevitropium is a bronchospasmolytic agent.
Status:
Investigational
Source:
NCT04150042: Phase 1 Interventional Recruiting Pancreatic Adenocarcinoma Metastatic
(2021)
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Status:
Investigational
Source:
NCT03698864: Phase 2 Interventional Completed Necrobiosis Lipoidica
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03620474: Phase 1/Phase 2 Interventional Completed Hepatitis C
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03262792: Not Applicable Interventional Completed Knee Osteoarthritis
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Neoandrographolide, one of the principal diterpene lactones, isolated from a medicinal herb Andrographis paniculata Nees. Andrographis paniculata (Burm. f.) Wall. ex Nees (Acanthaceae), also known as “kalmegh” in India, is a widely distributed plant in Asia. In many traditional formulations, the aerial parts have been used as anti-inflammatory and antipyretic drugs for the treatment of a variety of chronic and infectious diseases. Neoandrographolide possesses significant anti-inflammatory effects, which implies that it would be one of the major contributing components to participate in the anti-inflammatory effect of A. paniculata. and a potential candidate for further clinical trial.
Status:
Investigational
Source:
NCT03087955: Phase 2/Phase 3 Interventional Completed Trypanosomiasis, African
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Acoziborole (previously known as SCYX-7158) is a product of Anacor’s novel boron chemistry, which has produced a number of compounds with efficacy against a range of fungal, inflammatory, and bacterial diseases. Acoziborole was developed as an orally active compound with potent antitrypanosoma activity for the potential treatment of stage 2 human African trypanosomiasis (HAT) or sleeping sickness, a deadly parasitic disease transmitted by the tsetse fly. HAT is an important public health problem in sub-Saharan Africa. Existing therapies suffer from poor safety profiles, difficult treatment regimens, limited effectiveness, and a high cost of goods. Acoziborole is participating in phase II/III clinical trial to study its efficacy and safety in patients infected by HAT due to T.b. Gambiense.
